Bristol Myers Squibb (NYSE:BMY) versus Aditxt (NASDAQ:ADTX) Critical Analysis

Bristol Myers Squibb (NYSE:BMY) and Aditxt (NASDAQ:ADTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Volatility and Risk

Bristol Myers Squibb has a beta of 0.19, suggesting that its stock price is 81% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Bristol Myers Squibb and Aditxt, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1	15	11	2	2.48
Aditxt	1	0	0	0	1.00

Bristol Myers Squibb presently has a consensus target price of $64.96, suggesting a potential upside of 9.77%. Given Bristol Myers Squibb’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Bristol Myers Squibb is more favorable than Aditxt.

Insider & Institutional Ownership

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 15.5% of Aditxt shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Bristol Myers Squibb and Aditxt”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$48.19 billion	2.51	$7.05 billion	$4.54	13.04
Aditxt	$14,336.00	0.17	-$41.71 million	($100,788.35)	-0.00

Bristol Myers Squibb has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Bristol Myers Squibb and Aditxt’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Aditxt	-360,152.50%	-374.60%	-105.93%

Summary

Bristol Myers Squibb beats Aditxt on 14 of the 15 factors compared between the two stocks.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

About Aditxt

Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.